Clinical trials: Residual Disease
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer, Colon Cancer
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab).
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- NCT05900648
- Testing
- Regorafenib, XmAb20717
- Sponsor
- M.D. Anderson Cancer Center
CLL, SLL
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or…
- Conditions
- CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia
- Trial name
- NCT04694560
- Testing
- Treatment Free Observation
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Knee Osteoarthritis (Knee OA), Total Knee Anthroplasty
Drain Removal Before Versus After CPM in Primary Total Knee Arthroplasty
The aim of this prospective randomized controlled study was to determine whether the timing of drain removal in relation to continuous passive motion (CPM) application influences postoperative residual hematoma formation…
- Conditions
- Knee Osteoarthritis (Knee OA), Total Knee Anthroplasty, Postoperative Hematoma
- Trial name
- NCT07302724
- Testing
- Drain Removal Before CPM, Drain Removal After CPM
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Ankara Etlik City Hospital
Pseudophakia, Myopia
Treatment of Residual Refraction Errors 6 Months After Trifocal IOL Implantation With Relex-Smile
Successful treatment of residual refraction 6 months after IOL Implantation with Relex-Smile.
- Conditions
- Pseudophakia, Myopia, Hyperopia
- Trial name
- NCT04712318
- Testing
- Relex Smile, Relex smile with fresh corneal lenticule implantation
- Where
- Kosovo
- Volunteers
- 130 people
- Sponsor
- Eye Hospital Pristina Kosovo
Non Small Cell Lung Cancer, Stage III Lung Cancer
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery.
- Trial name
- RESCUE (NCT06878274)
- Testing
- Post-operative radiotherapy
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
End-stage Renal Disease (ESRD)
NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients
Hemodialysis (HD) is the main renal replacement therapy for patients with end-stage renal disease (ESRD), accounting for approximately 69% of all renal replacement therapies and 89% of all dialysis.
- Trial name
- HDRRFI-NIRS (NCT06243900)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yuanjun Yang
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Colorectal Cancer, Minimal Residual Disease
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
- Trial name
- NCT06358430
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Symptomatic Neuroma, Phantom Limb Pain After Amputation
Evaluation of RPNI for Symptomatic Neuromas in Lower Limb Amputees
This prospective, observational cohort study evaluates the long-term outcomes of Regenerative Peripheral Nerve Interface (RPNI) surgery in patients with major lower extremity amputations suffering from symptomatic neuromas.
- Conditions
- Symptomatic Neuroma, Phantom Limb Pain After Amputation, Residual Limb Pain, Neuropathic Pain
- Trial name
- RPNI-AMPUTEE (NCT07420192)
- Testing
- Regenerative Peripheral Nerve Interface (RPNI) Surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Saglik Bilimleri Universitesi
Acute Myeloid Leukemia
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.
- Trial name
- NCT04209712
- Testing
- haploid allogeneic NK cell therapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Preventing Malnutrition
Gastric Residual Volume Measurement in the Intensive Care Unit
Nutritional support is considered a key component of the treatment strategy for intensive care patients. Malnutrition, energy protein, and inadequate or excessive intake of other nutrients have measurable effects on tissues, body…
- Trial name
- NCT05238051
- Testing
- Gastric residual volume measurement stopped.
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Erzincan Binali Yildirim Universitesi
Breast Cancer, Residual Disease
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional…
- Conditions
- Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
- Trial name
- PREDICT-RD (NCT07069595)
- Testing
- Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Peripheral Arterial Disease
Residual Platelet Activity In Advanced Peripheral Artery Disease
The peripheral arterial disease (PAD) is a common atherosclerotic disease manifestation and its prevalence increase with age and with the simultaneous presence of cardiovascular risk factors.
- Trial name
- TRAIANO (NCT01627431)
- Testing
- Acetylsalicylic acid, Clopidogrel
- Where
- 2 sites in Italy
- Volunteers
- 410 people
- Sponsor
- University of Roma La Sapienza
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.